Gemcitabine in the treatment of ovarian cancer

Annals of Oncology

Volumn 10, Issue SUPPL. 1, 1999, Pages

  Hansen, S W ^a   Tuxen, M K ^a   Sessa, C ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b OSPEDALE SAN GIOVANNI   (Switzerland)

Author keywords

Carboplatin; Combination chemotherapy; Gemcitabine; Ovarian cancer; Paclitaxel

Indexed keywords

CARBOPLATIN; CISPLATIN; GEMCITABINE; PACLITAXEL;

AREA UNDER THE CURVE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CYTOTOXICITY; DNA REPAIR; DNA REPLICATION; DRUG EFFECT; ENZYME INHIBITION; FEVER; HUMAN; NEUTROPENIA; OVARY CANCER; PRIORITY JOURNAL; THROMBOCYTOPENIA;

EID: 0032964877     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0923-7534(20)31484-8     Document Type: Conference Paper

References (14)

1. Plunkett W, Huang P, Searcy CE, Gandhi V. Gemcitabine: Preclinical pharmacology and mechanisms of action. Semin Oncol 1996; 23 (Suppl 10): 3-15.
2. Huang P, Chubb S, Hertel LW et al. Action of 2′, 2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 1991; 51: 6110-17.
3. Bergman AM, van Haperen VWTR, Veerman G et al. Synergistic interaction between Cisplatin and Gemcitabine in vitro. Clin Cancer Res 1996; 2: 521-30.
4. Yang LY, Li L, Liu L et al. Gemcitabine suppresses the repair of cisplatin adducts in plasmid DNA by extracts of cisplatin-resistant human colon carcinoma cells. Proc Am Assoc Cancer Res 1995; 36: 357 (Abstr).
5. neul. Cancer Res 1996; 56: 794-801.
6. Lund B, Hansen OP, Theilade K et al. Phase II study of gemcitabine (2′,2′ difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 1994; 86: 1530-3.
7. Shapiro JD, Millward MJ, Rischin D et al. Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol 1996; 63: 89-93.
8. Underhill C, Parnis FX, Highley M et al. A phase II study of gemcitabine in previously untreated patients with advanced epithelial ovarian cancer (EOC). Ann Oncol 1996; 5 (Suppl 5): A 324 (Abstr).
9. Kunkel LM, Evans SS, Dottino PR et al. Cisplatin (CDDP) & gemcitabine (DFDC) in relapsed ovarian cancer. Proc Am Soc Clin Oncol 1998; 17: 1379 (Abstr).
10. Poole CJ, Perren T, Hogberg T et al. Phase I study to investigate the optimal dose and schedule of gemcitabine (G) and paclitaxel (P) in combination in patients with previously treated epithelial ovarian cancer. Proc Am Soc Clin Oncol 1998; 17: 1380 (Abstr).
11. Krakowski I, Petit T, Kayitalire L et al. Gemcitabine (Gemzar®) in combination with cisplatin (CP) in advanced ovarian cancers (AOC): A phase II study. Proc Am Soc Clin Oncol 1998; 17: 1373 (Abstr).
12. Bauknecht T, Grieshaber C, Breitbach G-P et al. Gemcitabine (Gem) in combination with cisplatin (CP) in previously untreated patients ≥ 60 years with FIGO stage IIIc or IV epithelial ovarian cancer: A phase II study: Preliminary results. Proc Am Soc Clin Oncol 1998; 17: 1376 (Abstr).
13. Nogué M, Cirera M, Arcusa I et al. Gemcitabine combined with cisplatin first line: A phase II study in patients with advanced epithelial ovarian cancer. Proc Am Soc Clin Oncol 1998; 17: 1377 (Abstr).
14. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1-6.